[go: up one dir, main page]

NO20056171L - Kombinasjonsterapi - Google Patents

Kombinasjonsterapi

Info

Publication number
NO20056171L
NO20056171L NO20056171A NO20056171A NO20056171L NO 20056171 L NO20056171 L NO 20056171L NO 20056171 A NO20056171 A NO 20056171A NO 20056171 A NO20056171 A NO 20056171A NO 20056171 L NO20056171 L NO 20056171L
Authority
NO
Norway
Prior art keywords
azd2171
human
antiangiogenic
warm
treated
Prior art date
Application number
NO20056171A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20056171L publication Critical patent/NO20056171L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for produksjon av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende stråling, spesielt en metode for behandling av kreft, spesielt kreft som involverer en fast tumor, som omfatter administrering av AZD2171 i kombinasjon med ZD6126; et farmasøytisk preparat omfattende AZD2171 og ZD6126; et kombinasjonsprodukt omfattende AZD2171 og ZD6126 for anvendelse ved en metode for behandling av en menneske- eller dyrekropp ved terapi; et sett omfattende AZD2171 og ZD6126; anvendelse av AZD2171 og ZD6126 ved fremstilling av et medikament for anvendelse for produksjon av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende stråling.
NO20056171A 2003-07-10 2005-12-23 Kombinasjonsterapi NO20056171L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316123.9A GB0316123D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002937 WO2005004871A1 (en) 2003-07-10 2004-07-07 Combination therapy

Publications (1)

Publication Number Publication Date
NO20056171L true NO20056171L (no) 2006-02-07

Family

ID=27741905

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056171A NO20056171L (no) 2003-07-10 2005-12-23 Kombinasjonsterapi

Country Status (18)

Country Link
US (1) US20060160775A1 (no)
EP (1) EP1651227B1 (no)
JP (1) JP2007526887A (no)
KR (1) KR20060034287A (no)
CN (1) CN100435799C (no)
AT (1) ATE385798T1 (no)
AU (1) AU2004255023B2 (no)
BR (1) BRPI0412450A (no)
CA (1) CA2531643A1 (no)
DE (1) DE602004011781T2 (no)
ES (1) ES2299841T3 (no)
GB (1) GB0316123D0 (no)
HK (1) HK1089384A1 (no)
IL (1) IL172682A0 (no)
MX (1) MXPA06000413A (no)
NO (1) NO20056171L (no)
WO (1) WO2005004871A1 (no)
ZA (1) ZA200600188B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
NZ549552A (en) * 2004-03-23 2009-12-24 Astrazeneca Ab Combination therapy involving 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (AZD2171) and a platinum anti-tumour agent
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
EP1965801B1 (en) * 2005-12-22 2011-03-23 AstraZeneca AB Combination of azd2171 and pemetrexed
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2335038A1 (en) * 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
SK288378B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Použitie chinazolínových derivátov ako inhibítorov angiogenézy
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
AU4258601A (en) * 2000-03-31 2001-10-15 Angiogene Pharm Ltd Divided dose therapies with vascular damaging activity
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
ZA200600188B (en) 2007-04-25
CN1819830A (zh) 2006-08-16
HK1089384A1 (en) 2006-12-01
BRPI0412450A (pt) 2006-09-19
CA2531643A1 (en) 2005-01-20
CN100435799C (zh) 2008-11-26
EP1651227A1 (en) 2006-05-03
ATE385798T1 (de) 2008-03-15
AU2004255023A1 (en) 2005-01-20
DE602004011781D1 (de) 2008-03-27
EP1651227B1 (en) 2008-02-13
MXPA06000413A (es) 2006-03-17
DE602004011781T2 (de) 2009-02-19
ES2299841T3 (es) 2008-06-01
WO2005004871A1 (en) 2005-01-20
US20060160775A1 (en) 2006-07-20
IL172682A0 (en) 2006-04-10
GB0316123D0 (en) 2003-08-13
AU2004255023B2 (en) 2007-09-27
JP2007526887A (ja) 2007-09-20
KR20060034287A (ko) 2006-04-21

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
NO20064755L (no) Kombinasjonsterapi
ZA200600188B (en) Combination therapy
NO20064754L (no) Kombinasjonsterapi
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application